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Interleukin-1 (IL-1) is a potent inflammatory cytokine that can be produced by a variety
of cell types throughout the body. While IL-1 is a central mediator of inflammation and
response to infection, the role of IL-1 signaling in adult and pediatric brain injury is becom-
ing increasingly clear. Although the mechanisms of IL-1 expression are largely understood,
the downstream effects and contributions to excitotoxicity and oxidative stress are poorly
defined. Here, we present a review of mechanisms of IL-1 signaling with a focus on the role
of IL-1 in perinatal brain injury. We highlight research models of perinatal brain injury and
the use of interleukin-1 receptor antagonist (IL-1RA) as an agent of therapeutic potential
in preventing perinatal brain injury due to exposure to inflammation.
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INTRODUCTION
Interleukin-1 (IL-1) is the name given to two cytokine peptides,
IL-1α and IL-1β, that bind and activate the IL-1 receptor (IL-
1R). IL-1 was first called endogenous pyrogen and described as a
protein isolated from polymorphonuclear leukocytes, that, when
injected into humans or animals, causes fever (1, 2). IL-1 is a
pro-inflammatory cytokine that mediates the immune response to
infection and inflammation and influences a broad range of physi-
ologic activity that includes acute-phase response gene expression,
T and B lymphocyte stimulation, cell survival, glial activation,
fever, hypotension, and leukopenia (3–6).
Mounting evidence suggests that IL-1 signaling plays a cen-
tral role in mediating chronic and acute brain injury in both adult
and pediatric populations. IL-1 receptor antagonist (IL-1RA) is an
endogenous inhibitor of IL-1 signaling and recombinant IL-1RA is
widely used in adults for treatment of autoimmune and inflamma-
tory diseases such as rheumatoid arthritis and inflammatory bowel
disease (5). There is emerging evidence that perinatal administra-
tion of IL-1RA may confer neuroprotective effects during births at
high risk for brain injury (7, 8). Here, we offer a review of IL-1 and
the therapeutic potential of IL-1RA in preventing brain injury in
neonates following exposure to inflammation [either intrauterine
inflammation preceding preterm birth, chorioamnionitis, or birth
following hypoxia–ischemia (HI)].
IL-1 RECEPTOR
The IL-1R is comprised of two membrane proteins, IL-1R1
and IL-1R accessory protein (IL-1RAcP), and binds IL-1α, IL-
1β, IL-1RA, and IL-38. IL-1R1 and IL-1RAcP contain an intra-
cellular Toll/interleukin-1 receptor (TIR) homology domain
that recruits myeloid differentiation primary response protein
88 (MyD88) upon receptor heterodimerization (4, 9). MyD88,
an adapter protein, recruits the IL-1R associated kinase 4
(IRAK4), which initiates a signaling cascade by phosphory-
lating and activating IRAK1, which, in turn, activates and
recruits TRAF6 to the IL-1R complex. TRAF6 mediates signal-
ing through two pathways. One pathway leads to the activa-
tion of the transcription factor NFκB through the activation
of TAB2 and TAK1. The other pathway leads to the acti-
vation of the c-jun/c-fos heterodimeric activating protein 1
(AP-1) transcription factor complex through the MAPK/JNK
pathway. NFκB and AP-1 activation drives expression of the
pro-inflammatory genes TNF-α, IL-6, and IL-1, generating an
acute-phase response (10, 11).
A decoy receptor made up of IL-1R2 and IL-1RAcP also binds
IL-1β but IL-1R2 lacks an intracellular activation domain (12). IL-
1α and IL-1β bind IL-1R2 with much greater affinity than IL-1R1.
The difference in affinity for the decoy receptor effectively creates
a cytokine trap that neutralizes free IL-1 without inflammatory
signaling (13). Additionally, an endogenous receptor antagonist,
discussed in greater detail below, has a much lower affinity for IL-
R2. Together, the decoy receptor and antagonist provide a potent
mechanism of regulating IL-1 signaling.
IL-1α AND IL-1β
Both IL-1α and IL-1β transcripts are translated into precursor pep-
tides. However, while pro-IL-1β requires proteolytic cleavage to
generate the mature, active form of the cytokine, pro-IL-α is func-
tionally active. Thus, IL-1α, which is expressed in epithelial cells
of the gastrointestinal tract, kidney, liver, lung, endothelial cells,
and astrocytes, rapidly initiates inflammatory responses when
released by necrotic cell death, as occurs following ischemic events.
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IL-1β is expressed in hematopoietic cells, including macrophages,
dendritic cells, monocytes, and microglia, and in endothelial cells.
Expression of IL-1β is triggered by Toll-like receptor 4 (TLR4)
signaling, IL-6 signaling, or by IL-1β itself. As many cell types
express the IL-1R, IL-1 signaling can be paracrine or autocrine.
The production and release of IL-1β is highly regulated by cells.
TLR signaling is required for the expression and translation of
pro-IL-1β. Maturation of IL-1β requires cleavage of pro-IL-1β by
Caspase 1. Caspase 1 activity is regulated by the NLRP3 inflamma-
some. The inflammasome can be activated by numerous stimuli,
including pathogen associate molecular patterns (PAMPS), exter-
nal ATP and glucose, and molecules that signal of stress or danger
(14, 15).
IL-1 RECEPTOR ANTAGONIST
The IL-1 receptor antagonist (IL-1RA) is an endogenous ligand
that binds the IL-1R but does not recruit the IL-1RAcP, thereby
preventing activation of the receptor (Figure 1). IL-1RA also has
a higher affinity for the IL-1R than IL-1α or IL-1β and serves to
limit pro-inflammatory IL-1 signaling by blocking binding of the
active cytokines (16). Deficiencies in IL-1RA result in a reduction
of regulatory function and can result in severe inflammation and
autoinflammatory disorders such as arthritis, vasculitis, and skin
lesions in humans (17–19). IL-1RA knockout mice develop similar
phenotypes to those seen in human disease, including arthropathy
and arterial inflammation (20–22).
IL-1RA, IL-1α, and IL-1β have been shown to cross the blood–
brain barrier by a saturable mechanism (23). In rat models of
stroke, rIL-RA, delivered subcutaneously or intravenously, can
reach therapeutic concentrations in the cerebrospinal fluid within
FIGURE 1 | Mechanism of interleukin-1 (IL-1) receptor antagonist
(IL-1RA) blockade. IL-1 is produced in response to hypoxia or Toll-like
receptor (TLR) activation. The IL-1 receptor (IL-1R) is comprised of an
IL-1R1 subunit and an IL-1R accessory protein (IL-1RAcP). IL-1RA
binds IL-1R1 with a higher affinity than IL-1α or IL-1β, but does not recruit
IL-1RAcP. Without heterodimerization of the IL-1 receptor complex, no
signaling occurs. Binding of IL-1α or IL-1β to IL-1R1 recruits IL-1RAcP and
intracellular signaling is initiated, leading to the expression of acute-phase
response genes such as IL-1, interleukin-6 (IL-6), and tumor necrosis
factor-alpha (TNF-α). In the brain, these pro-inflammatory cytokines induce
neuroinflammation, including neuronal injury and astrogliosis.
45 min (24, 25). While the placenta can secrete IL-RA in response
to lipopolysaccharide, to date, no studies have addressed placental
transfer of rIL-1RA (26). Placental perfusion studies have found
that several cytokines, including IL-1β, TNF-α, and IL-6, do not
cross the placenta and this may hold true for rIL-1RA (27–29).
Pharmacokinetic studies are warranted to determine the poten-
tial efficacy of maternally administered rIL-1RA in the setting of
preterm birth. In considering possible future clinical applications,
rIL-1RA may need to be delivered via amniocentesis if placental
transfer is insufficient to generate therapeutic doses in the fetal
compartment. With future advances and knowledge of molecu-
lar action of IL-1RA, we speculate that small molecules may be
designed that will mimic IL-1RA activity and would be able to
cross the placenta.
CLINICAL TRIALS WITH IL-1RA
In 1993, Amgen introduced the first drug targeting IL-1 sig-
naling, a recombinant IL-1RA (rIL-1RA), Anakinra (Kineret).
rIL-1RA is produced in E. coli and was approved by the FDA
for treatment of rheumatoid arthritis in 2001. In 2012, rIL-
RA was approved for treatment of neonatal-onset multisystem
inflammatory disease (NOMID). Five randomized, double-blind,
placebo-controlled trials that included over 3000 patients were
conducted (30–34). Mertens and Singh offer a critical review
of the rIL-1RA clinical trials (35). Briefly, the trials found rIL-
1RA to be significantly more effective than placebo in improv-
ing outcomes with no difference in adverse events, deaths, and
study withdrawals.
Interest in recombinant rIL-1RA therapy for additional diseases
continues, and at this time there are 21 ongoing clinical trials to
treat a range of diseases including diabetes, breast cancer, chronic
fatigue, and heart failure (Table 1). Recent mechanistic studies
have reported that rIL-1RA has neuroprotective effects in rodent
models of perinatal brain injury (7, 8, 24, 25).
IL-1RA IN BRAIN INJURY
Many antenatal, perinatal, or postnatal factors, whether genetic
or environmental, can lead to postnatal brain injury. Chronic
events prior to parturition may be of greater importance than
acute events, as the chronic conditions may be overlooked until
postnatal clinical symptoms are evident. Additionally, the timing
of the insult influences the nature of the brain injury. Preterm
infants are more likely to suffer from intraventricular hemor-
rhage and periventricular leukomalacia, while term infants expe-
rience focal ischemia, injury to basal ganglia, and subcortical
hemorrhage (36).
Pathogen-induced inflammation and/or HI are the major
insults resulting in postnatal neurological impairment through
the release of inflammatory mediators, such as members of the
IL-1 family (37–43). Human neuropathological studies and exper-
imental animal models of postnatal brain injury reveal that pro-
inflammatory cytokines, especially IL-1β, are implicated in the
cascade leading to brain damage at different developmental stages
(41, 44–50). Therefore, postnatal systemic administration of IL-
1RA may be a potential therapeutic intervention of postnatal brain
injury (7, 51).
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Table 1 | Ongoing rIL-1RA clinical trials.
Study title Phase Primary outcome measures Anakinra dose
Anakinra combined with chemotherapy and
dendritic cell vaccine to treat breast cancer
1/2 Safety of DC vaccine combined with chemotherapy, and
DC vaccine combined with chemotherapy and anakinra
100 mg/day
subcutaneous
Infants and children with coronary artery
abnormalities in acute Kawasaki disease
1/2 Safety of a 6-week course of anakinra 2 mg/kg/day
4 mg/kg/day
Adult patients with colchicine-resistant familial
Mediterranean fever
3 Number of patients with less than a mean of one FMF
attack per month
100 mg/day
subcutaneous
Safety and blood immune cell study of anakinra
in metastatic breast cancer patients
1 Safety – adverse events in participants 100 mg/day
subcutaneous
Anakinra or denosumab and everolimus in
advanced cancer
1 Maximum tolerated dose (MTD) 100 mg/day
subcutaneous
Efficacy study of anakinra, pentoxifylline, and
zinc compared to methylprednisolone in severe
acute alcoholic hepatitis
2/3 Death|MELD score 100 mg/day
subcutaneous
Safety and tolerability of anakinra in combination
with riluzol in amyotrophic lateral sclerosis
2 Number and severity of adverse events, pathological
laboratory parameters
100 mg/day
subcutaneous
IL-1 blockade in acute myocardial infarction
(VCU-ART3)
2/3 Acute response (CRP levels) 100 mg/day
subcutaneous
Study evaluating the influence of LV5FU2
bevacizumab plus anakinra association on
metastatic colorectal cancer
2 Response rate after 2 months in patients with colorectal
cancer with liver metastases treated with anakinra and
LV5FU2/bevacizumab
100 mg/day
subcutaneous
Evaluation of the safety of anakinra plus
standard chemotherapy
1 The number of participants with serious adverse events
and adverse events
100 mg/day
subcutaneous
IL-1 blockade in acute heart failure (anakinra
ADHF)
2/3 C reactive protein 200 mg/day for 3 days
(high dose)
100 mg/day (standard
dose)
Interleukin-1 blockade in recently
decompensated heart failure
2/3 Placebo-corrected interval changes in peak VO2 and
VE/VCO2 slope
100 mg/day
subcutaneous
Inflammatory pustular skin diseases 2 Obtain an estimate of the response rate to treatment 100–300 mg/day
subcutaneous
Effect of anakinra on insulin sensitivity in type 1
diabetes mellitus
2 Insulin sensitivity as determined by euglycemic
hyperinsulinemic clamp
100 mg/day
subcutaneous
Gene expression profiling in PBMCs as a tool
for prediction of anakinra responsiveness in
rheumatoid arthritis
4 Observational 100 mg/day
subcutaneous
Role of interleukin-1 in postprandial fatigue 1 Postprandial fatigue 100 mg subcutaneous
Immunomodulation, IL-1 inhibition, and
postoperative incisional pain
N/Aa Concentration levels of inflammatory mediators (IL-1,
IL-6, IL-8, and TNF-α) present in human wounds following
surgery with and without the use of anakinra
N/Aa
Cytokine inhibition in chronic fatigue syndrome
patients
2/3 CIS (checklist individual strength, compared to baseline) 100 mg/day
subcutaneous
A dose-block randomized, placebo controlled
(double-blind), active controlled(open-label),
dose-escalation study
1 Tolerability, pharmacokinetics of HL2351,
Immunogenicity of HL2351, Tolerability,
pharmacokinetics, and pharmacodynamics of HL2351 in
comparison with kineret (anakinra), IL-6 inhibition assay
100 mg/day
subcutaneous
Anti-IL-1 treatment in children DKA at diagnosis
of type 1 diabetes
2 Number of adverse events 2 mg/kg bolus followed
by 2 mg/kg/h infusion
Interleukin-1 blockade in HF with preserved EF 2 Aerobic exercise capacity, ventilatory efficiency 100 mg/day
subcutaneous
aData not available.
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IL-1RA AND PATHOGENIC MODELS OF POSTNATAL BRAIN
INJURY
Several models of inflammatory postnatal brain injury have been
developed in different species, including mouse (52–56), rat (57–
59), rabbit (60, 61), dog (62), and others (63). Rodent models are
most widely used due to ease of use and relatively short repro-
ductive cycle. Administration of pathogens, such as virus (52),
bacteria (64), pathogenic infectious components (57, 61), and pro-
inflammatory cytokines (46, 65) varies widely between models in
timing, from prenatal to postnatal stage, and route of delivery,
whether intranasal (52, 66), intravenous (67), intrauterine (68,
69), intraperitoneal (59), or intracerebral injection (70).
IL-1RA has been shown to be neuroprotective (71–73) in ani-
mal models of traumatic brain injury and excitotoxicity in vivo
and in vitro, in which IL-1β exerts a dominant role pathologi-
cally. In rodent models of postnatal brain injury, the elevation
of IL-1β and other pro-inflammatory cytokines was observed
(69, 74, 75), indicating the importance of the IL-1β signaling
pathway in postnatal brain injury. Leitner et al. applied rIL-1RA
systemically at embryonic day 15, 30 min prior to administra-
tion of intrauterine injection of lipopolysaccharide. They found
rIL-1RA improved fetal cortical neuronal injury without affect-
ing the rate of preterm birth. This might be via the blockade
of neuronal nitric oxide synthase (8). Furthermore, Girard et al.
administrated a low dose of rIL-1RA to pups in a systemic
inflammatory animal model and a hypoxic-ischemia model post-
natally (7, 76). This treatment preserved motor function and
exploratory behavior. Neuroprotective effects were evident by
increased neural stem cell populations, prevention of myelin loss,
and decreased gliosis. This study provides a potential candidate
for postnatal treatment of brain injury, especially in the earli-
est days of life in the term infant. Savard et al. used systemic
infection–inflammation combined with HI in a rat model at post-
natal day 12, which exerted a synergistic detrimental effect on
rat brain, leading to a peculiar pattern of parasagittal cortical–
subcortical infarcts mimicking those in the human full-term new-
born with subsequent severe neurodevelopmental impairments.
rIL-1RA administration reduced the extent of brain lesions by
MRI observation (50).
IL-1RA AND HYPOXIA–ISCHEMIA ASSOCIATED POSTNATAL
BRAIN INJURY MODEL
Hypoxia–ischemia is another common cause of postnatal brain
injury. The most widely used HI model is the Vannucci model,
which combines permanent unilateral ligation of the carotid
artery in 7-day-old rat pups, along with exposure to hypoxia (77–
80). Increased expression of pro-inflammatory cytokines includ-
ing IL-1β is associated with HI-induced postnatal brain injury
(81–83).
Experimental administration of rIL-1RA has been demon-
strated to reduce HI-induced postnatal brain injury (84–86).
Martin et al. injected rIL-1RA subcutaneously in a postnatal rat
HI model and found prior to or after HI, rIL-1RA ameliorated the
ischemia damage as measured by hemisphere dry weights and pre-
vented neuronal loss in the striatum (87). Hu et al. injected 2µg
rIL-1RA intra-cerebroventricularly 2 h after HI and found a signif-
icant reduction in cell death and Caspase 3 activity. The observed
increase in cytoplasmic NFκB activation and nuclear transloca-
tion of Bcl-3 24 h after HI was also significantly attenuated by IL-1
blockade, suggesting that HI-induced IL-1 activation is via both
the NFκB activation and the nuclear translocation of Bcl-3 (88).
Though a rapidly expanding body of evidence indicates that
rIL-1RA is a promising therapeutic for postnatal brain injury, the
specific signaling mechanisms triggered by rIL-1RA responsible
for the effects are still not fully known. A number of drawbacks
of rIL-1RA limit its broader use; these include injection site reac-
tions (89, 90), broad immunosuppression (90), and high costs.
Trials to test safety in a pediatric population are sorely needed as a
lack of efficacy and safety data limits the adoption of rIL-1RA for
perinatal brain injury.
CONCLUDING REMARKS
During infection and inflammation, the potent effects of IL-1 sig-
naling can lead to devastating tissue damage with long-lasting
effects. Therapies that block IL-1 signaling have been successful
in reducing negative outcomes in autoinflammatory diseases in
adults for over a decade now. Exciting research in the area of neona-
tal encephalopathy suggests that the benefits of IL-1 blockade in
reducing injury in autoinflammatory diseases may be extended to
neonatal brain injury and offer much needed neuroprotection for
a population with limited effective treatment options.
Neonatal encephalopathy affects up to 1% of live births (91–
93) and the causes can vary from hypoxic–ischemic events to
intrauterine inflammation (37, 38, 40–43). Treatment options are
limited and the current standard of care prescribes therapeutic
hypothermia (94). Hypothermia, however, does not confer com-
plete neuroprotection and as many as 50% of treated neonates
will experience moderate to severe neurologic disability (95).
Common processes that contribute to neuronal injury, includ-
ing oxidative stress, apoptosis, inflammation, and excitotoxicity,
are increasingly the targets of emerging therapies for neonatal
encephalopathy.
As a Class B drug, rIL-1RA is approved for use in pregnant
women and may be offered in the future as a perinatal intervention
to prevent perinatal brain injury due to neonatal encephalopa-
thy or due to exposure to intrauterine inflammation. However,
rIL-1RA is not approved for the treatment or prevention of peri-
natal brain injury, and further studies are needed to determine its
safety and efficacy. At this time, little is known in regards to the
importance of IL-1 in brain formation or the development of the
immature immune system; therefore, further evaluation of this
molecule is necessary to establish appropriate safe timing of its
administration for variety of etiologies of perinatal brain injury.
Furthermore, no studies have yet been conducted to assess the
efficacy of rIL-1RA in combination with other therapies, such as
hypothermia, although other combination therapies (hypother-
mia and erythropoietin) have shown promise in rodent models
(96, 97). Mechanistic studies of r-IL1RA, as we are conducting, are
ongoing to evaluate maternal–fetal transfer and developmental
effects in animal models.
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